M3-BRIGADE ACQUISITION II-A (MBAC) Fundamental Analysis & Valuation

NYSE:MBAC • US5538001034

10.59 USD
+0.01 (+0.09%)
Last: Dec 8, 2023, 08:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MBAC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MBAC. MBAC was compared to 0 industry peers in the Unkown industry. The financial health of MBAC is average, but there are quite some concerns on its profitability. MBAC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. MBAC Profitability Analysis

1.1 Basic Checks

  • In the past year MBAC was profitable.
  • MBAC had a negative operating cash flow in the past year.
MBAC Yearly Net Income VS EBIT VS OCF VS FCFMBAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 0 10M 20M 30M

1.2 Ratios

Industry RankSector Rank
ROA 14.71%
ROE 24.91%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBAC Yearly ROA, ROE, ROICMBAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 2 4 6 8

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MBAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBAC Yearly Profit, Operating, Gross MarginsMBAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MBAC Health Analysis

2.1 Basic Checks

  • MBAC has about the same amout of shares outstanding than it did 1 year ago.
  • MBAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBAC Yearly Shares OutstandingMBAC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 10M 20M 30M 40M
MBAC Yearly Total Debt VS Total AssetsMBAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

  • MBAC has an Altman-Z score of 3.92. This indicates that MBAC is financially healthy and has little risk of bankruptcy at the moment.
  • There is no outstanding debt for MBAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.92
ROIC/WACCN/A
WACCN/A
MBAC Yearly LT Debt VS Equity VS FCFMBAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 100M 200M 300M

2.3 Liquidity

  • MBAC has a Current Ratio of 0.10. This is a bad value and indicates that MBAC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • A Quick Ratio of 0.10 indicates that MBAC may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
MBAC Yearly Current Assets VS Current LiabilitesMBAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MBAC Growth Analysis

3.1 Past

  • MBAC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.94%.
EPS 1Y (TTM)-46.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. MBAC Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 40.73, the valuation of MBAC can be described as expensive.
  • The average S&P500 Price/Earnings ratio is at 25.71. MBAC is valued rather expensively when compared to this.
Industry RankSector Rank
PE 40.73
Fwd PE N/A
MBAC Price Earnings VS Forward Price EarningsMBAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBAC Per share dataMBAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MBAC Dividend Analysis

5.1 Amount

  • No dividends for MBAC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MBAC Fundamentals: All Metrics, Ratios and Statistics

M3-BRIGADE ACQUISITION II-A

NYSE:MBAC (12/8/2023, 8:04:01 PM)

10.59

+0.01 (+0.09%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners2.17%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap153.98M
Revenue(TTM)N/A
Net Income(TTM)7.00M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 40.73
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.48
P/tB 5.48
EV/EBITDA N/A
EPS(TTM)0.26
EY2.46%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS1.93
TBVpS1.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 14.71%
ROE 24.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 3.92
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.63%
OCF growth 3YN/A
OCF growth 5YN/A

M3-BRIGADE ACQUISITION II-A / MBAC FAQ

Can you provide the ChartMill fundamental rating for M3-BRIGADE ACQUISITION II-A?

ChartMill assigns a fundamental rating of 1 / 10 to MBAC.


Can you provide the valuation status for M3-BRIGADE ACQUISITION II-A?

ChartMill assigns a valuation rating of 0 / 10 to M3-BRIGADE ACQUISITION II-A (MBAC). This can be considered as Overvalued.


Can you provide the profitability details for M3-BRIGADE ACQUISITION II-A?

M3-BRIGADE ACQUISITION II-A (MBAC) has a profitability rating of 0 / 10.


Can you provide the PE and PB ratios for MBAC stock?

The Price/Earnings (PE) ratio for M3-BRIGADE ACQUISITION II-A (MBAC) is 40.73 and the Price/Book (PB) ratio is 5.48.